Eisai (company)

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Eisai" company – news · newspapers · books · scholar · JSTOR (January 2018) (Learn how and when to remove this message) You can help expand this article with text translated from the corresponding article in Japanese. (March 2020) Click [show] for important translation instructions. View a machine-translated version of the Japanese article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consider adding a topic to this template: there are already 1,301 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Japanese Wikipedia article at [[:ja:エーザイ]]; see its history for attribution. You may also add the template {{Translated|ja|エーザイ}} to the talk page. For more guidance, see Wikipedia:Translation. (Learn how and when to remove this message)

Eisai Co., Ltd.

Native name	エーザイ株式会社
Romanized name	Ēzai kabushiki gaisha
Company type	Public KK
Traded as	TYO: 4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component
Industry	Pharmaceuticals
Founded	December 6, 1941; 82 years ago (1941-12-06)
Founder	Toyoji Naito
Headquarters	4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people	Haruo Naito (President and CEO)
Products	Lecanemab Lenvema Halaven Aricept Pariet Banzel Zonegran Fycompa Zebinix
Revenue	¥ 741.8 billion (2023)[1]
Operating income	¥ 53.4 billion (2023)[1]
Net income	¥ 43.8 billion (2023)[1]
Total assets	¥ 743.9 billion (2023)[1]
Total equity	¥ 430.2 billion (2023)[1]
Owner	The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%)[2]
Number of employees	10,000 (2023)[1]
Website	Official website
Footnotes / references [2] [1]

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.^[3]

Nihon Eisai Co. Ltd. was established in 1941.^[4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.^[5] The American subsidiary of the company, Eisai Inc., was established in 1995.^[6]

On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer.^[7]

Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.^[8]

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion.^[9] This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).^[10]

In June 2023, the company suffered from a ransomware attack, causing a shutdown of some of its logistical systems.^[11]

Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.^[12] The approval was converted into a traditional approval in July 2023.^[13]

Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.^[14] Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.^[15][16]

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Some of the key products that Eisai produces or markets with partners include:

• Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease
• Actonel (risedronic acid) - Osteoporosis (Japan)
• Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting
• Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients
• Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome
• Belviq (lorcaserin) - Obesity
• Dayvigo (lemborexant) - Insomnia
• Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism
• Fycompa (perampanel) - Partial-onset seizures
• Gliadel Wafer (carmustine) - Treatment for Brain Tumors
• Halaven (eribulin) - Metastatic breast cancer
• Iomeron (iomeprol) - Non-ionic contrast medium
• Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer
• Leqembi (lecanemab) - Alzheimer's disease
• Methylcobal (methylcobalamin) - Peripheral neuropathy
• Myonal (eperisone) - Muscle relaxant
• Selbex (teprenone) - Gastric ulcers and gastritis
• Zonegran (zonisamide) - Partial-onset seizures

Aricept accounted for 40% of Eisai's revenue as of March 2010.^[17] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.^[17] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.^[17]

• Biotech and pharmaceutical companies in the New York metropolitan area

• Official website